Revance Therapeutics, Inc.

Revance Therapeutics — Technical Presentation (May 2017)

12 slides from Revance Therapeutics's technical presentation, May 18, 2017

  1. Slide 1: CL005: DaxibotulinumtoxinA for Injection (RT002) Topline Week 24 Results

    Revance TherapeutIcs CL005: DaxibotulinumtoxinA for Injection (RT002) Investigational Product for the Treatment of Cervical Dystonia Topline Week 24 Results for Phase 2 Open-Label Study Exhibit 99.1

  2. Slide 2: Study Objectives, Primary & Secondary Endpoints

    Study Objectives To assess the safety and preliminary efficacy of RT002 for Injection in subjects with isolated CD To evaluate the duration of effect of RT002 for Injection in the treatment of isolated CD Primary Endpoint: Improvement of dystonia, as measured by change from baseline in TWSTRS-Total

  3. Slide 3: Cervical Dystonia Phase 2 Study Design

    Cervical Dystonia Phase 2 Study Design RT002 up to 200 U iDMC (4-6 week safety) Interim Data Monitoring Committee (4-6 week safety) RT002 200 to 300 U RT002 300 to 450 U Eligibility Criteria Patients with Moderate to Severe CD: TWSTRS*-Total score ≥ 20 TWSTRS-Severity subscale ≥ 15 Cohort 1 (n=12) C

  4. Slide 4: Demographics by Cohort

    Demographics by Cohort Cohort 1 (N=12) Cohort 2 (N=12) Cohort 3 (n=13) All (n=37) Mean age (range) 57 (46--74) 52 (32--70) 58 (30--69) 56 (30--74) Females, n (%) 11 (92%) 8 (67%) 9 (69%) 28 (76%) Mean RT002 dose, U, (range) 174 (100 to 200) 229 (200 to 300) 323 (300 to 450) 244 (100 to 450) Mean CD

  5. Slide 5: Number (%) of Subjects with Treatment-Related AEs by Cohort

    Number (%) of Subjects with Treatment-Related AEs by Cohort By Preferred Term Cohort 1 (N=12) Cohort 2 (N=12) Cohort 3 (n=13) All (n=37) Number of treatment-related AEs 8 8 6 22 Subjects with any treatment-related AE, n (%)* 6 (50%) 5 (42%) 2 (15%) 13 (35%) Dysphagia 1 (8%) 2 (17%) 2 (15%) 5 (14%)**

  6. Slide 6: Primary Endpoint by Cohort: Reduction in TWSTRS-Total Score at Week 4

    Primary Endpoint by Cohort Reduction in TWSTRS-Total Score at Week 4 Note: Two subjects currently on study had missing value at Week 4 38% 46% 28% 41% Clinically Meaningful Reduction in TWSTRS-Total Score Observed at Week 4 across all 3 Cohorts

  7. Slide 7: Secondary Endpoint by Cohort: Change from Baseline in TWSTRS-Total Score

    Secondary Endpoint by Cohort Change from Baseline in TWSTRS-Total Score over Time Clinically meaningful improvement in TWSTRS-Total Score observed at Week 2 increased through Week 6, with almost all of this benefit maintained in Cohorts 1 & 3 through Week 24

  8. Slide 8: Secondary Endpoint by Cohort: Duration of Response

    *Of subjects with improvement at Week 4. Withdrawals due to need for retreatment are considered as events. Secondary Endpoint by Cohort Duration of Response Defined by Subject Reaching Target-TWSTRS Score* Median Duration of Response of > 24 Weeks Observed across all 3 Cohorts Median Duration Cohort

  9. Slide 9: Subject Distribution by Dose

    Subject Distribution by Dose Study Doses administered cluster into Two Separate Dose Groups Dose Group A 100U - 240U n=21 Dose Group B 300U - 450U n=16 Cohort 1 Cohort 2 Cohort 3 Number of Subjects Dose

  10. Slide 10: Secondary Endpoint by Dose Group

    Secondary Endpoint by Dose Group Change from Baseline in TWSTRS-Total Score over Time Clinically meaningful improvement in TWSTRS-Total Score observed at Week 2 increased through Week 6, with the majority of this benefit maintained in both dose groups through Week 24

  11. Slide 11: Safety Summary

    Safety Summary RT002 appeared to be generally safe and well tolerated through Week 24 across all dose groups evaluated, with no increase in Treatment-Emergent AEs (TEAEs) upon dose escalation Total of 22 Treatment-Related TEAEs reported in 13 of 37 subjects (35%) Most frequently reported: dysphagia

  12. Slide 12: Efficacy Summary

    Efficacy Summary Duration of Effect: The median duration of effect, defined as subjects maintaining at least 20% of the treatment benefit achieved at Week 4 (Target TWSTRS Score), was > 24 Weeks for each of the 3 cohorts studied When analyzed by Dose Groups A and B, the median duration of effect was

Revance Therapeutics — Technical Presentation (May 2017) on 6ix